LOGOPHARM GmbH

LOGOPHARM GmbH is engaged in proteomic target and biomarker R&D. The biotech company was established 2005 in Freiburg (Germany) by a team of scientists and business experts. It combines proprietary proteomic technologies, long-term experience in functional membrane protein analysis and innovative drug development concepts with focus on membrane proteins and protein complexes. Proprietary developments include the CompleXio technology for identification of protein-protein interactions in native tissue, microproteomic analysis with ultimate sensitivity and label-free quantitative mass spectrometry. Based on this, we offer advanced proteomic R&D services, tools and antibodies as well as technology and target-related developments.